Physician profile
Liye Li
NPI 1538498639
$7,354.36
in general payments reported to CMS, 2019-2025
24 companies · $866 in 2025
The $866 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $1,672 · 2021: $334 · 2022: $924 · 2023: $888 · 2024: $2,102 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,419.01 | 2019-2025 | Vemlidy, Livdelzi |
| Bayer Healthcare Pharmaceuticals INC. | $551.87 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.49 | 2023-2024 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $420.20 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $337.98 | 2020-2025 | Repatha, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $273.21 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $260.26 | 2019-2023 | Watchman Access System |
| Glaxosmithkline, LLC. | $197.90 | 2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $167.28 | 2022-2024 | |
| Novo Nordisk INC | $149.14 | 2022-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $136.15 | 2022 | |
| Medtronic, INC. | $135.30 | 2022 | |
| Madrigal Pharmaceuticals | $129.63 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Exact Sciences Corporation | $112.69 | 2023-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $94.77 | 2024-2025 | Zoryve |
| Nuvasive, INC. | $90.91 | 2022 | |
| Amarin Pharma, INC. | $80.61 | 2019-2021 | |
| Phadia US INC. | $50.47 | 2019-2024 | Immunocap |
| Pfizer INC. | $41.86 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $26.30 | 2022 | |
| Hologic Sales and Service, LLC | $21.64 | 2025 | Aptima |
| Esperion Therapeutics, INC. | $18.23 | 2021 | |
| Genentech USA, INC. | $13.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liye Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.